CTOs on the Move

Luca Technologies

www.lucatechnologies.com

 
Luca Technologies, Inc. engages in the development of long-term biotechnology-driven solutions to the natural gas market in the United States.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Tekia

Tekia is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CSL Behring

CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products and providing them to people in more than 100 countries.

Financial Medical Systems

Financial Medical Systems, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Financial Medical Systems, Inc. is based in Hauppauge, NY. You can find more information on Financial Medical Systems, Inc. at www.finmedsys.com

Granville Health System

Granville Health System is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Oxford, NC. To find more information about Granville Health System, please visit www.granvillemedical.com

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.